Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Free Report) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 5,915 shares, a decrease of 82.9% from the August 31st total of 34,593 shares. Based on an average daily trading volume, of 38,250 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.4% of the shares of the company are short sold.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Global X Genomics & Biotechnology ETF stock. Bank of America Corp DE boosted its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Free Report) by 67.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 119,795 shares of the company’s stock after purchasing an additional 48,394 shares during the period. Bank of America Corp DE owned approximately 10.70% of Global X Genomics & Biotechnology ETF worth $5,240,000 at the end of the most recent quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.
Global X Genomics & Biotechnology ETF Trading Down 0.1%
NASDAQ GNOM traded down $0.08 on Friday, hitting $70.17. 76,480 shares of the company’s stock traded hands, compared to its average volume of 18,609. The firm’s 50-day moving average price is $61.52 and its two-hundred day moving average price is $52.90. The firm has a market capitalization of $105.25 million, a PE ratio of -29.99 and a beta of 1.19. Global X Genomics & Biotechnology ETF has a 1-year low of $37.25 and a 1-year high of $70.83.
Global X Genomics & Biotechnology ETF Company Profile
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.
Featured Stories
- Five stocks we like better than Global X Genomics & Biotechnology ETF
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
